Molecular Characterization of the Interaction of Staphylococcal Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM) ClfA and Fbl with Fibrinogen*

Joan A. Geoghegan‡, Vannakambadi K. Ganesh‡, Emanuel Smeds§, Xiaowen Liang‡, Magnus Höök§, and Timothy J. Foster††

From the ‡Microbiology Department, Moyne Institute of Preventive Medicine, Trinity College, Dublin 2, Ireland and the §Center for Infectious and Inflammatory Diseases, Institute for Biosciences and Technology, Texas A & M Health Science Center, Houston, Texas 77030-3303

The ligand-binding domain of Fbl (the fibrinogen binding protein from Staphylococcus lugdunensis) shares 60% sequence identity with ClfA (clumping factor A) of Staphylococcus aureus. Recombinant Fbl corresponding to the minimum fibrinogen-binding region (subdomains N2N3) was compared with ClfA for binding to fibrinogen. Fbl and ClfA had similar affinities for fibrinogen by surface plasmon resonance. The binding site for fibrinogen was localized to the extreme C terminus of the fibrinogen γ-chain at the same site recognized by ClfA. Isothermal titration calorimetry showed that Fbl and ClfA had very similar affinities for a peptide mimicking the C-terminal segment of the fibrinogen γ-chain. The peptide also inhibited binding of Fbl and ClfA to fibrinogen. A series of substituted γ-chain variant peptides behaved very similarly when used to inhibit ClfA and Fbl binding to immobilized fibrinogen. Both ClfA and Fbl bound to bovine fibrinogen with a lower affinity compared with human fibrinogen and did not bind detectably to ovine fibrinogen. The structure of the N2N3 subdomains of Fbl in complex with the fibrinogen γ-chain peptide was modeled based on the crystal structure of the N2N3 subdomains of the ClfA-γ-chain peptide complex. Residues in the putative binding trench likely to be involved in fibrinogen binding were identified. Fbl variant proteins with alanine substitutions in key residues had reduced affinities for fibrinogen. Thus Fbl and ClfA bind the same site in fibrinogen by similar mechanisms.

Staphylococcus aureus is an important human pathogen that colonizes the moist squamous epithelium in the anterior nares. It causes both superficial skin infections and more invasive diseases such as endocarditis, osteomyelitis, and septic arthritis. Staphylococcus lugdunensis is a coagulase negative staphylococcus that is a commensal of the human skin. It can occasionally cause serious infections similar to those caused by S. aureus (1).

S. lugdunensis expresses a fibrinogen-binding surface protein (Fbl) with considerable similarity to ClfA (clumping factor A) of S. aureus (2, 3). ClfA is a microbial surface component recognizing adhesive matrix molecules (MSCRAMM) that binds to fibrinogen (Fg) and fibrin (4). ClfA promotes bacterial adhesion to immobilized Fg, to blood clots, to ex vivo biomaterial conditioned with plasma proteins, and to sterile thrombi on the heart valves of rabbits and rats in models of endocarditis (5, 6). ClfA is also antiphagocytic and protects bacteria from opsonophagocytosis (7, 8), which might explain its role as a virulence factor in infection models of sepsis and arthritis (9).

The structure and organization of Fbl are very similar to ClfA (2, 3). The N-terminal A domain of ClfA binds to Fg (10). It is composed of three separately folded subdomains: N1, N2, and N3 (11). Subdomains N1 of ClfA and Fbl have 19% amino acid identity, whereas the subdomains N2N3 share almost 60% identity (2). The A domains are linked to the cell wall-anchor domain by serine-rich repeats (tandem SD repeats in the case of ClfA and SDSDSA repeats for Fbl).

The N2N3 subdomains form the minimum fibrinogen-binding site of ClfA. ClfA binds to a peptide sequence comprising the extreme C terminus of the γ-chain of Fg that protrudes from the D domain (12). The x-ray crystal structure of ClfA N2N3 has been solved both as an apoprotein and in complex with a peptide mimicking the C terminus of the γ-chain (11, 13). The γ-chain peptide binds predominantly in a hydrophobic trench formed between the separately folded N2 and N3 subdomains.

ClfA binds to fibrinogen by a variation of the “dock, lock, and latch” mechanism of ligand binding (13). The dock, lock, and latch mechanism was proposed and validated for the structurally related SdrG from Staphylococcus epidermidis, which binds to the N-terminal β-chain peptide protruding from domain E of fibrinogen (14, 15). The apo-form of the protein adopts an open conformation. Docking of the Fg peptide in the hydrophobic trench between the N2 and N3 subdomains induces a redirection of the C-terminal extension of subdomain N3, resulting in it covering the trench with the bound peptide, thus locking it in place and interacting with the subdomain N2 by making β-strand complementation (14, 15). For SdrG, an open form of the protein is required to bind its ligand. ClfA can bind to the Fg

*This work was supported, in whole or in part, by National Institutes of Health Grant AI20624 (to M. H.). This work was also supported by a Health Research Board of Ireland project grant and a Science Foundation Ireland Programme Investigator grant (to T. J. F.).

†To whom correspondence should be addressed. Tel.: 353-1-8962014; Fax: 353-1-6799294; E-mail: tfoster@tcd.ie.

2 The abbreviations used are: MSCRAMM, microbial surface component recognizing adhesive matrix molecules; Fg, fibrinogen; ITC, isothermal titration calorimetry; PBS, phosphate-buffered saline.
γ-chain even in an artificially constrained closed form where the C-terminal extension of subdomain N3 is held in place in N2 by a disulfide bond (13). Residues at the extreme C terminus of the γ-chain of Fg are crucial for ligand binding because removal of two residues from the C terminus of a 17-mer γ-chain peptide abolished binding to ClfA. The model was supported by substituting several residues in the binding trench of ClfA that were predicted to be involved in ligand binding.

This study describes a detailed comparison of the mechanism of binding to Fg by Fbl and ClfA and concludes that the two staphylococcal proteins are functionally very similar. This striking similarity suggests that new anti-staphylococcal compounds mimicking the C terminus of the γ-chain may be designed to simultaneously target both ClfA and Fbl.

**MATERIALS AND METHODS**

**Bacterial Strains and Growth Conditions**—Escherichia coli strain XL-1 Blue (Stratagene) was used as the host for selecting recombinant plasmids following cloning or mutagenesis. E. coli strain TOPP 3 (Stratagene) was used for expression of recombinant proteins and grown in Luria broth supplemented with ampicillin (100 μg/ml) at 37 °C.

**Expression and Purification of Recombinant Proteins**—Plasmid pKS80::fbl (2) containing the entire coding region of the fbl gene of *S. lugdunensis* strain N920143 was used as a template for amplification of the region encoding amino acids 206–533 and 40–533, respectively, using primers incorporating BglII restriction sites. Plasmid pQE30 (Qiagen) was manipulated to replace the BamHI site of the multiple cloning site with a BglII site. PCR products were cloned into this modified vector allowing N-terminal hexahistidine-tagged proteins to be expressed. Plasmids pCF41 and pCF40 are derivatives of pQE30 containing codons for ClfA amino acids 221–559 and 40–559, respectively (16). Recombinant His-tagged proteins were expressed and purified by Ni²⁺ chelate chromatography as described previously (16).

**Generation of a Three-dimensional Model of rFbl206–533**—Sequence alignment using the LALIGN server (17) showed no gaps in the sequences between ClfA and Fbl. A homology model of the Fbl-Fg γ-chain peptide complex in closed conformation was generated using the crystal structure of the ClfA-Fg γ-chain D410A peptide complex (13) as template. The structure of the Fbl N2N3 subdomains (Fbl206–533) was modeled with the HOMOLOGY module of InsightII software (Accelrys Inc.) using the sequence alignment from LALIGN. The wild-type sequence of γ-chain rather than the D410A variant was used for modeling. The resulting model did not show any steric violation between the γ-chain peptide and Fbl. The stereochemical parameters of the model were checked using PROCHECK (18). The figures with ribbon models were generated using RIBBONS (19).

**Site-directed Mutagenesis**—Site-directed mutagenesis was performed using the QuikChange method (Stratagene). Overlapping complementary primers containing the appropriate base changes (Table 1) were used to amplify the pQE30 plasmid containing the DNA encoding amino acids 206–533 of Fbl. Cycling conditions used were as outlined by the QuikChange protocol. The products were digested with DpnI to eliminate parental DNA and transformed into *E. coli* XL-1 Blue. The mutations were verified by sequencing (GATC Biotech).

**Synthesis of Peptides**—A synthetic peptide comprising the 17 C-terminal residues of human Fg was synthesized by Genscript (Piscataway, NJ). The human 15-mer and the putative ovine 15-mer were synthesized as previously described (12) and purified using high pressure liquid chromatography.

**Inhibition Assays**—Recombinant Fbl or ClfA were preincubated with a range of concentrations of a synthetic peptide comprising the 17 C-terminal residues of the γ-chain of Fg or variant peptides with alanine (or serine) substitutions at each position (Table 2) for 1 h at room temperature. A solution of Fg in PBS (10 μg/ml) was used to coat microtiter wells (Sarstedt) for 18 h at 4 °C. The wells were washed three times with PBS and blocked with 5% (w/v) skimmed milk in PBS for 2 h at 37 °C. The wells were washed again, and recombinant proteins were added. The plates were incubated for 1.5 h at 37 °C. Unbound protein was removed by washing with PBS. Bound protein was detected by incubation with anti-His₆-peroxidase (Roche Applied Science) at 37 °C for 1 h and detected as described previously (20). The percentage of inhibition was calculated relative to the level of bound protein detected in the absence of inhibitor peptide.

**TABLE 1**

| Name             | Sequence                                  |
|------------------|-------------------------------------------|
| Fbl40–533 forward| GEGQQHHLGGAKQAGDV                        |
| Fbl reverse      | GEGQQHHLGGAKQAGDV                        |
| Fbl206–533 forward| GEGQQHHLGGAKQAGDV                        |
| N270A forward   | GEGQQHHLGGAKQAGDV                        |
| Y322A reverse   | GEGQQHHLGGAKQAGDV                        |
| Y322A reverse   | GEGQQHHLGGAKQAGDV                        |
| W507A forward   | GEGQQHHLGGAKQAGDV                        |
| W507A forward   | GEGQQHHLGGAKQAGDV                        |
| E510A forward   | GEGQQHHLGGAKQAGDV                        |
| E510A reverse   | GEGQQHHLGGAKQAGDV                        |

* The restriction sites are in bold type.

**TABLE 2**

| Peptide name | Substitution          | Sequence |
|--------------|-----------------------|----------|
| Human 17-mer |                       | GEGQQHHLGGAKQAGDV |
| P1           | G395A                 | GEGQQHHLGGAKQAGDV |
| P2           | E396A                 | GEGQQHHLGGAKQAGDV |
| P3           | G397A                 | GEGQQHHLGGAKQAGDV |
| P4           | Q398A                 | GEGQQHHLGGAKQAGDV |
| P5           | Q399A                 | GEGQQHHLGGAKQAGDV |
| P6           | H400A                 | GEGQQHHLGGAKQAGDV |
| P7           | H401A                 | GEGQQHHLGGAKQAGDV |
| P8           | L402A                 | GEGQQHHLGGAKQAGDV |
| P9           | G403A                 | GEGQQHHLGGAKQAGDV |
| P10          | G404A                 | GEGQQHHLGGAKQAGDV |
| P11          | A405S                 | GEGQQHHLGGAKQAGDV |
| P12          | K406A                 | GEGQQHHLGGAKQAGDV |
| P13          | Q407A                 | GEGQQHHLGGAKQAGDV |
| P14          | A408S                 | GEGQQHHLGGAKQAGDV |
| P15          | G409A                 | GEGQQHHLGGAKQAGDV |
| P16          | D410A                 | GEGQQHHLGGAKQAGDV |
| P17          | V411A                 | GEGQQHHLGGAKQAGDV |
| Ovine 15-mer |                       | GEGQQHHLGGAKQAGDV |
| Human 15-mer |                       | GEGQQHHLGGAKQAGDV |

* Deviations from the human sequence are in underlined.
Enzyme-linked Immunosorbent Assay—Recombinant ClfA or Fbl was coated onto microtiter plates (Nunc) in sodium carbonate buffer (pH 9.6) for 18 h at 4 °C. The wells were washed three times with PBS and blocked with 5% (w/v) skimmed milk proteins in PBS for 2 h at 37 °C. The wells were washed again, and varying dilutions of polyclonal rabbit anti-ClfA or anti-Fbl antibodies were added to the wells and incubated for 1 h at room temperature. The wells were washed three times with PBS, and goat anti-rabbit IgG horseradish peroxidase-conjugated antibodies (Dako) were added to the wells and incubated for 1 h. After washing three times with PBS, bound horseradish peroxidase-conjugated antibodies were detected as described previously (20).

Isothermal Titration Calorimetry—ITC was performed with a VP-ITC or ITC200 microcalorimeter (MicroCal Inc., Northampton, MA) stirring at 1000 rpm at 30 °C. In a typical experiment, the cell contained 30 μM rFbl206–533 or rClfA221–559, and the syringe contained 0.5–1 mM peptide. Both solutions were in HBS buffer (10 mM HEPES, 150 mM NaCl, pH 7.4). To take into account the heat of dilution, two blank titrations were performed, one by injecting peptide into buffer and the other by injecting buffer into the protein solution. The averaged heats of dilution were subtracted. The data were analyzed using MicroCal Origin software (version 5.0), fitting them to a single site model.

Surface Plasmon Resonance—SPR was performed using the BIAcore X100 system (GE Healthcare). Human Fg purified from contaminating fibronectin, von Willebrand factor, and plasminogen (Enzyme Research Laboratories, South Bend, IN) was covalently immobilized on CM5 sensor chips using amine coupling. This was performed using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, followed by N-hydroxysuccinimide and ethanolamine hydrochloride, as described by the manufacturer. Fg (10 μg/ml) was dissolved in 10 mM sodium citrate at pH 5.5 and then immobilized on the flow cell at a flow rate of 30 μl/min in PBS. On another flow cell, the dextran matrix was treated as described above but without Fg present to provide an uncoated reference flow cell. Increasing concentrations of recombinant proteins were flowed over immobilized Fg at a rate of 5 μl/min.

For murine monoclonal antibody 12-9, a capture approach was used. Rabbit anti-mouse Fc IgG (Pierce) was diluted in 10 mM sodium acetate buffer at pH 4.5 and immobilized on two flow cells by amine coupling as described above. The 12-9 murine monoclonal antibody (100 μg/ml) in PBS was passed over the anti-mouse Fc IgG surface of one flow cell, and the other flow cell served as a reference. Recombinant ClfA221–559 (100 nM) and rFbl206–533 (100 nM) were flowed over the surface at a rate of 5 μl/min.

All of the sensorgram data presented were subtracted from the corresponding data from the reference flow cell. The response generated from injection of buffer over the chip was also subtracted from all of the sensorgrams. The data were analyzed using the BIAevaluation software version 3.0. A plot of the
level of binding (response units) at equilibrium against concentration of analyte was used to determine the $K_D$.

**RESULTS**

**Measurement of the Dissociation Constant for Fibrinogen by Surface Plasmon Resonance**—The full-length recombinant Fbl A domain (N1N2N3; rFbl40–533) and the N2N3 subdomains (rFbl206–533) were expressed with N-terminal His6 tags (Fig. 1A). The affinity of these proteins for fibrinogen was measured and compared with recombinant His6-tagged ClfA N1N2N3 domains (rClfA40–559) and ClfA N2N3 domains (rClfA221–559) using SPR (Fig. 1, B and C). Increasing concentrations of recombinant proteins were flowed over a chip that had been coated with Fg. From analysis of the equilibrium binding data, the dissociation constant ($K_D$) of the interaction between rFbl40–533 and Fg was determined to be 0.79 ± 0.09 M, enthalpy $\Delta H = -7.7$ kcal/mol, and molar binding stoichiometry $n = 1.26$; for ClfA, the dissociation constant $K_D = 0.15 \times 10^{-6}$ M, enthalpy $\Delta H = -3.7$ kcal/mol, and molar binding stoichiometry $n = 1.2$.

**Isothermal Titration Calorimetry**—ClfA binds to the extreme C terminus of the $\gamma$-chain of Fg (12). Because recombinant ClfA could block binding of Fbl to Fg (2) and given the high level of similarity between ClfA and Fbl binding domains, it seemed likely that the two proteins would bind to the same region of Fg. Thus the affinities of rClfA221–559 and rFbl206–533 for a synthetic peptide corresponding to the C-terminal 17 amino acids of the $\gamma$-chain were measured by ITC. Recombinant Fbl206–533 bound with a $K_D$ of 9 ± 0.1 M (Fig. 2A), whereas rClfA221–559 had a $K_D$ of 15 ± 2 M (Fig. 2B). These experiments showed that Fbl bound to the C terminus of the Fg $\gamma$-chain and that the affinity of Fbl for the peptide is very similar to that of ClfA.

**Inhibition of Binding**—To further investigate the interaction between Fbl and the C-terminal residues of Fg, the 17-mer $\gamma$-chain peptide was tested for its ability to inhibit the binding of rFbl206–533 to immobilized Fg. This peptide was previously shown to inhibit recombinant ClfA and FnBPA A domain binding to Fg (21). Preincubation of rFbl206–533 or rClfA221–559 with increasing concentrations of peptide resulted in dose-dependent inhibition of binding (Fig. 3A). This confirms that the Fg binding site for Fbl in Fg is the C-terminal residues of the $\gamma$-chain. The maximum inhibition achieved by the $\gamma$-chain peptide was ~50% for Fbl and ~60% for ClfA.

Inhibition of rFbl206–533 and rClfA221–559 binding to Fg was measured using $\gamma$-chain peptides with single alanine (or serine) substitutions in each of the terminal 17 residues (13). The variant peptides had the same effect on rFbl206–533 and rClfA221–559 binding to Fg. Peptides with G395A, H400A,
Interaction of MSCRAMMs ClfA and Fbl with Fibrinogen

FIGURE 3. Inhibition of rFbl206–533 and rClfA221–559 binding to immobilized fibrinogen by γ-chain peptide. Recombinant Fbl206–533 (100 nM) (C) and rClfA221–559 (100 nM) (●) were incubated with increasing concentrations of the Fg γ-chain peptide for 1 h before being added to the wells of microtiter plates coated with Fg (A). Alternatively, rFbl206–533 (60 nM) (B, upper panel) or rClfA221–559 (100 nM) (B, lower panel) was incubated with γ-chain peptide variants P1–P17 (Table 2) for 1 h before being added to Fg-coated plates. Bound proteins were detected using anti-His6-peroxidase antibody. The values are expressed as percentages of control wells lacking inhibitor peptide. The filled boxes (B) represent peptides showing increased inhibition compared with wild-type (wt) peptide. The results shown are the mean values of triplicate samples. These experiments were performed three times with similar results.

G403A, G404A, K406A, Q407A, A408S, and G409A substitutions had reduced ability to inhibit both ClfA and Fbl compared with the native peptide (Fig. 3B). Variants Q398A, L402A, A405S, D410A, and V411A had an increased inhibitory effect on both ClfA and Fbl binding to Fg. Amino acid substitutions that increase or reduce inhibition by the peptide presumably alter the affinity of the peptide for ClfA and Fbl, indicating that these residues are important in the interaction with the MSCRAMM. Substitutions E396D and G397A, and H401A had little effect on the inhibition of either protein binding to Fg. This indicates that the interaction of ClfA and Fbl with the C-terminal residues of the γ-chain of Fg is very similar.

**Binding to Fibrinogen from Different Species**—The ability of rClfA and rFbl to bind Fg from different species was compared. Differences in the C-terminal γ-chain residues might influence the affinities of ClfA and Fbl and could be informative. Microtiter plates were coated with human, bovine, ovine, murine, feline, canine, and porcine Fg. Both ClfA and Fbl bound to canine, murine, and porcine Fg at similar levels to human Fg (Fig. 4). In contrast, both ClfA and Fbl bound weakly to bovine Fg and did not bind to ovine Fg. The one difference between the two MSCRAMMs was the weak binding of Fbl to feline Fg compared with ClfA, which bound with the same avidity as it did to human Fg (Fig. 4). Thus Fbl and ClfA behave almost identically with the exception of the binding to feline Fg.

The ovine Fg γ-chain is not annotated in the public databases. A bioinformatic search was performed for ovine expressed sequence 15-mer (Table 2). The human peptide bound to ClfA with a $K_D$ of $44 \pm 8.6 \mu M$ and to Fbl with a $K_D$ of $40 \pm 6.9 \mu M$ (data not shown), but the 15-mer ovine peptide did not bind detectably to either MSCRAMM (data not shown). This suggests that the failure of Fbl and ClfA to bind to the ovine γ-chain may be due to the Q407K substitution in the C terminus of the ovine Fg γ-chain.

To examine this in more detail, structural models of both Fbl and ClfA in complex with the Q407K variant peptide were generated. The crystal structure of the ClfA-Fg γ-chain peptide complex (13) was used as template. Visual examination of the model suggests that the bulky Lys407 residue (human Fg numbering) of the ovine Fg sequence clashes with Thr383 and the backbone atoms of Ile384 of ClfA (Fig. 4C), preventing the ovine sequence from fitting into the binding trench and abolishing the interaction with ClfA. In addition, changing a polar uncharged glutamine to a positively charged lysine could impose charge-charge repulsion with any of the surrounding positively charged residues such as His252 or Lys381. Thus the loss of binding of ClfA and Fbl to ovine Fg may be due to the Q407K substitution in the C terminus of the ovine Fg γ-chain.

**Amino Acid Substitution Mutants of Fbl**—The homology model of the Fbl-Fg γ-chain peptide complex (based on the structure of the ClfA-Fg γ-chain D410A peptide complex) (13) was used to identify residues in the putative ligand-binding trench of Fbl that might be involved in Fg binding (Fig. 5). Residues lining the trench region located between N2 and N3 are tag clones using BLAST (tblastn module) (22). The sequence of the C-terminal residues of the human γ-chain (residues 351–411) was used as template. This generated a liver cDNA sequence (GenBank™ accession number gi 114476568) with a matching stop codon and 90% identity to the human C-terminal sequence. When the sequences were aligned, the putative ovine sequence had an apparent gap at human position 395 and substitutions E396D and Q407K. The crystal structure of the ClfA-Fg γ-chain complex (13) showed that Gln407 of Fg makes key interactions with ClfA and is completely buried in the complex. Furthermore, the alanine scan of γ-chain peptide (Fig. 3) showed that substitution of a bulky glutamine residue with alanine (Q407A) reduced binding to ClfA or Fbl. To determine whether the Q407K variation is responsible for the inability of ClfA and Fbl to bind ovine Fg, a peptide corresponding to the C-terminal 15 residues of the predicted ovine Fg γ-chain was compared with the equivalent human Fg γ-chain.
completely conserved between ClfA and Fbl in contrast to residues located elsewhere where 40% divergence occurs.

Amino acid substitutions were made in four residues in the putative ligand-binding trench of Fbl that could possibly interact with the $\gamma$-chain of Fg (Asn270, Tyr322, Trp507, and Glu510; Fig. 5, right panel). The same residues are located at equivalent positions (Asn286, Try338, Trp523, and Glu526) in ClfA. The crystal structure of the ClfA-Fg $\gamma$-chain complex demonstrates a direct interaction between the side chains of residues Tyr338 and Trp523 and the Fg peptide (13). The backbone atoms of the residues Glu526 and Asn286 of ClfA play a role in anchoring the peptide through hydrogen bonding interactions (13). Previous studies have demonstrated the importance of residues Tyr338 and Glu526 in fibrinogen binding by ClfA (11, 23, 24).

The affinity of each of the rFbl mutants for Fg was determined by SPR (Fig. 6). Analysis of the equilibrium binding data showed that rFbl N270A and rFbl E510A had slightly reduced affinity for Fg compared with rFbl206–533 ($K_D$ of 1.17 $\pm$ 0.29 and 1.74 $\pm$ 0.17 M, respectively compared with 0.59 $\pm$ 0.11 M for wild type). Amino acids in the loop regions around the ligand-binding trench are critical for optimum binding even when their side chains are not directly involved. The P336A substitution near the binding site in ClfA reduced Fg binding (25) but did not participate directly in the interaction (13). The crystal structure of the ClfA-Fg $\gamma$-chain complex demonstrates a direct interaction between the side chains of residues Tyr338 and Trp523 and the Fg peptide (13). The backbone atoms of the residues Glu526 and Asn286 of ClfA play a role in anchoring the peptide through hydrogen bonding interactions (13). Previous studies have demonstrated the importance of residues Tyr338 and Glu526 in fibrinogen binding by ClfA (11, 23, 24).

The affinity of each of the rFbl mutants for Fg was determined by SPR (Fig. 6). Analysis of the equilibrium binding data showed that rFbl N270A and rFbl E510A had slightly reduced affinity for Fg compared with rFbl206–533 ($K_D$ of 1.17 $\pm$ 0.29 and 1.74 $\pm$ 0.17 M, respectively compared with 0.59 $\pm$ 0.11 M for wild type). Amino acids in the loop regions around the ligand-binding trench are critical for optimum binding even when their side chains are not directly involved. The P336A substitution near the binding site in ClfA reduced Fg binding (25) but did not participate directly in the interaction (13). Res-
idue Asn<sup>270</sup> in Fbl is located in a loop in the N2 domain (Fig. 5), and the N270A substitution at the binding site could alter the conformation around the residue and also affect the interaction through the main chain atoms.

The E526A substitution is at the linker region before the latch and could affect optimal redirection of the latch segment and backbone hydrogen bonding interaction (13). The rFbl W507A and rFbl Y322A mutants had much weaker affinity for Fg. Recombinant Fbl W507A was estimated to have a $K_D$ of ~28.65 μM for fibrinogen (Fig. 6C), whereas the response for rFbl Y322A was so low that the $K_D$ could not be determined with any reliability (Fig. 6D). Thus Fbl residues Tyr<sup>322</sup> and Trp<sup>507</sup> appear to play an important role in Fg binding by Fbl.

**Cross-reactivity of Polyclonal Anti-ClfA and Anti-Fbl Antibodies**—Comparison of the x-ray crystal structure of ClfA with the modeled structure of Fbl indicated that the majority of variant residues are located on the surfaces of the proteins (data not shown). The cross-reactivity of rabbit polyclonal anti-ClfA A domain antibodies had a 32-fold lower titer for rFbl<sup>206–533</sup>, whereas polyclonal anti-Fbl A domain antibodies had a 2-fold lower titer for rClfA<sup>221–559</sup> (Fig. 7). Both recombinant proteins reacted equally with monoclonal anti-His<sub>6</sub>-peroxidase antibody (data not shown), indicating that they coated the dish similarly. In addition, an important function-blocking anti-ClfA monoclonal antibody 12-9 (26) that binds with high affin-
Interaction of MSCRAMMs ClfA and Fbl with Fibrinogen

Interaction of MSCRAMMs ClfA and Fbl with Fibrinogen

The three-dimensional structure of the apo-protein and ligand bound form of ClfA has been solved. It is possible to model the structure of Fbl based on its amino acid sequence similarity and structural similarity to ClfA. Amino acid residues in the ligand-binding trench are completely conserved in contrast to residues located elsewhere on the protein. Four residues in the putative ligand-binding trench of Fbl were substituted, and the variant proteins showed a reduction in ligand binding by SPR. This confirms that Fbl and ClfA bind to Fg similarly and that the Fbl ligand binding site is the trench located between subdomains N2 and N3. Solving the crystal structures of Fbl in complex with γ-chain peptide will provide further insight into the mechanism of Fg binding by Fbl. Overall it appears that the ClfA and Fbl interaction with Fg is very similar. This similarity may be used to design new anti-staphylococcal compounds mimicking the Fg γ-chain C terminus that would have an effect against both S. aureus and S. lugdunensis.

Acknowledgment—We thank Dr. A. Khan (School of Biochemistry and Immunology, Trinity College, Dublin, Ireland) for use of the ITC200 calorimeter.

REFERENCES

1. Frank, K. L., Del Pozo, J. L., and Patel, R. (2008) Clin. Microbiol. Rev. 21, 111–133
2. Mitchell, J., Tristan, A., and Foster, T. J. (2004) Microbiology 150, 3831–3841
3. Nilsson, M., Bjerketorp, J., Guiss, B., and Frykberg, L. (2004) FEMS Microbiol. Lett. 241, 87–93
4. McDevitt, D., Francois, P., Vaudaux, P., and Foster, T. J. (1994) Mol. Microbiol. 11, 237–248
5. Moreillon, P., Enzenta, J. M., Francioli, P., McDevitt, D., Foster, T. J., Francois, P., and Vaudaux, P. (1995) Infect. Immun. 63, 4738–4743
6. Que, Y. A., Haeffiger, J. A., Piroth, L., Francois, P., Widmer, E., Enzenta, J. M., Sinha, B., Herrmann, M., Francioli, P., Vaudaux, P., and Moreillon, P. (2005) J. Exp. Med. 201, 1627–1635
7. Hair, P. S., Ward, M. D., Semmes, O. J., Foster, T. J., and Cunnion, K. M. (2008) J. Infect. Dis. 198, 125–133
8. Higgins, J., Loughman, A., van Kessel, K. P., van Strijp, J. A., and Foster, T. J. (2006) FEMS Microbiol. Lett. 258, 290–296
9. Josefsson, E., Hartford, O., O’Brien, L., Patti, J. M., and Foster, T. (2001) J. Infect. Dis. 184, 1572–1580
10. McDevitt, D., Francois, P., Vaudaux, P., and Foster, T. J. (1995) Mol. Microbiol. 16, 895–907
11. Deivanayagam, C. C., Wann, E. R., Chen, W., Carson, M., Rajashankar, K. R., Höök, M., and Narayana, S. V. (2002) EMBO J. 21, 6660–6667
12. McDevitt, D., Nanavaty, T., House-Pompeo, K., Bell, E., Turner, N., McIntire, L., Foster, T., and Höök, M. (1997) Eur. J. Biochem. 247, 416–424
13. Ganesh, V. K., Rivera, J., Smeds, E., Ko, Y. P., Bowden, M. G., Wann, E. R., Gurusiddappa, S., Fitzgerald, J. R., and Höök, M. (2008) PLoS Pathog. 4,
Interaction of MSCRAMMs ClfA and Fbl with Fibrinogen

e1000226
14. Ponnuraj, K., Bowden, M. G., Davis, S., Gurusiddappa, S., Moore, D., Choe, D., Xu, Y., Hook, M., and Narayana, S. V. (2003) Cell 115, 217–228
15. Bowden, M. G., Heuck, A. P., Ponnuraj, K., Kolosova, E., Choe, D., Gurusiddappa, S., Narayana, S. V., Johnson, A. E., and Höök, M. (2008) J. Biol. Chem. 283, 638–647
16. O'Connell, D. P., Nanavaty, T., McDevitt, D., Gurusiddappa, S., Höök, M., and Foster, T. J. (1998) J. Biol. Chem. 273, 6821–6829
17. Huang, X. M., and Miller, W. (1991) Adv. Appl. Math 12, 337–357
18. Laskowski, R. A., Moss, D. S., and Thornton, J. M. (1993) J. Mol. Biol. 231, 1049–1067
19. Carson, M. (1997) J. Mol. Graph. 5, 103–106
20. Keane, F. M., Loughman, A., Valtulina, V., Brennan, M., Speziale, P., and Foster, T. J. (2007) Mol. Microbiol. 63, 711–723
21. Wann, E. R., Gurusiddappa, S., and Hook, M. (2000) J. Biol. Chem. 275, 13863–13871
22. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Mol. Biol. 215, 403–410
23. Deivanayagam, C. C., Perkins, S., Danthuluri, S., Owens, R. T., Bice, T., Nanavathy, T., Foster, T. J., Höök, M., and Narayana, S. V. (1999) Acta Crystallogr. D Biol. Crystallogr. 55, 554–556
24. Hartford, O. M., Wann, E. R., Höök, M., and Foster, T. J. (2001) J. Biol. Chem. 276, 2466–2473
25. Loughman, A., Fitzgerald, J. R., Brennan, M. P., Higgins, J., Downer, R., Cox, D., and Foster, T. J. (2005) Mol. Microbiol. 57, 804–818
26. Hall, A. E., Domanski, P. J., Patel, P. R., Vernachio, J. H., Syribeys, P. J., Gorovits, E. L., Johnson, M. A., Ross, J. M., Hutchins, J. T., and Patti, J. M. (2003) Infect. Immun. 71, 6864–6870